Shire is shifting focus to its human genetics unit
UK pharmaceutical company Shire announced a 23% rise in fourth-quarter profit.
Net income rose to $174.3m (£113m), from $141.3m a year ago.
The growth was mainly due to higher sales of Vyvanse, its drug treating attention deficit and hyperactivity disorder (ADHD).
Another contributor was its unit that produces drugs for rare genetic diseases, which benefited from problems at rival Genzyme.
The result was better than expected and the shares are currently up just over 4%.
Shire expects a return to revenue growth after 2009, where sales were flat at $3bn.
The company reiterated its goal of annual average percentage growth in sales in the "mid-teens" until 2015.
Revenues from Vyvanse rose 41% to $145m in the quarter, beating some analysts' estimates.
Shire's Vyvanse and its new Intuniv ADHD pill for children is now competing with significantly a cheaper generic version of its Adderall drug - the forerunner to Vyvanse - that has appeared on the market since April.
Shire is also shifting focus to its human genetics unit, which has benefited from US regulators suspending production of Genzyme Corp's competing Gaucher disease treatment, Cerezyme, in June after contamination at a factory.